Výsledky vyhledávání

Akademický článek

Tracing back primed resistance in cancer via sister cells

Publikováno v: Nature Communications, Vol 15, Iss 1, Pp 1-14 (2024)

Abstract Exploring non-genetic evolution of cell states during cancer treatments has become attainable by recent advances in lineage-tracing methods. However, transcriptional changes that drive cells into resistant fates may be subtle, necessitating

Externí odkaz: https://doaj.org/article/cb6fd31ba8b2481198015e55a8c83a4c

Zobrazit plný text záznamu

Akademický článek

Single-cell characterization of anti–LAG-3 and anti–PD-1 combination treatment in patients with melanoma

Publikováno v: The Journal of Clinical Investigation, Vol 133, Iss 6 (2023)

Background Relatlimab plus nivolumab (anti–lymphocyte-activation gene 3 plus anti–programmed death 1 [anti–LAG-3+anti–PD-1]) has been approved by the FDA as a first-line therapy for stage III/IV melanoma, but its detailed effect on the immune

Externí odkaz: https://doaj.org/article/45e8a21ae8814471ba60e41684de20f1

Zobrazit plný text záznamu

Akademický článek

Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia

Publikováno v: Haematologica, Vol 108, Iss 7 (2022)

The BCL-2 inhibitor venetoclax has revolutionized the treatment of acute myeloid leukemia (AML) in patients not benefiting from intensive chemotherapy. Nevertheless, treatment failure remains a challenge, and predictive markers are needed, particular

Externí odkaz: https://doaj.org/article/ed146fcdf2474b39baf1bf345a6c2b2c

Zobrazit plný text záznamu

Akademický článek

Targeting Apoptosis Pathways With BCL2 and MDM2 Inhibitors in Adult B-cell Acute Lymphoblastic Leukemia

Autor: Helena Hohtari, Matti Kankainen, Shady Adnan-Awad, Bhagwan Yadav, Swapnil Potdar, Aleksandr Ianevski, Olli Dufva, Caroline Heckman, Veronika Sexl, Soili Kytölä, Satu Mustjoki, Kimmo Porkka

Publikováno v: HemaSphere, Vol 6, Iss 3, p e701 (2022)

In adult patients, the treatment outcome of acute lymphoblastic leukemia (ALL) remains suboptimal. Here, we used an ex vivo drug testing platform and comprehensive molecular profiling to discover new drug candidates for B-ALL. We analyzed sensitivity

Externí odkaz: https://doaj.org/article/8ef93768f7754e64a0bfcedd49b3938c

Zobrazit plný text záznamu

Akademický článek

Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target

Publikováno v: Nature Communications, Vol 9, Iss 1, Pp 1-12 (2018)

Aggressive natural killer-cell leukemia (ANKL) has few targeted therapies. Here ANKL patients are reported to harbor STAT3, RAS-MAPK pathway, DDX3X and epigenetic modifier mutations; and drug sensitivity profiling uncovers the importance of the JAK-S

Externí odkaz: https://doaj.org/article/a90516e221ea4f0c9791e1e130cc3ead

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání